Advances in Immunotherapies for Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.03.17
- VernacularTitle:非小细胞肺癌免疫治疗进展
- Author:
HE YUAN
1
;
YOU CHANGXUAN
Author Information
1. 南方医科大学
- Keywords:
Lung neoplasms;
Immunotherapies;
Progress
- From:
Chinese Journal of Lung Cancer
2014;(3):277-281
- CountryChina
- Language:Chinese
-
Abstract:
Globally, Lung cancer is the leading cause of cancer-related death of high morbidity and mortality with poor prognosis, which needs some more effective and less toxic therapies. hTe immunotherapies offer a novel approach for the treatment of patients with non-small cell lung cancer (NSCLC) in both the adjuvant and palliative disease settings. A number of promising immunotherapies based on different mechanism have now been evaluated showing an increasing response rate. Moreover, further phase II/III clinical trials will be indicated to explore its value. hTese include checkpoint inhibitors (anti-CT-LA4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody), active vaccination (L-BLP25 liposome vaccine, Belagenpumatucel-L vaccine, MAGE-A3 protein vaccine) and adoptive vaccination (CIK cells). hTe purpose of this paper will draw a summary on the theory, clinical trials, toxicity and problems to be solved of the immunotherapies in NSCLC.
